Bastien Nguyen
Overview
Explore the profile of Bastien Nguyen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1050
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zammarrelli 3rd W, Nandakumar S, Kertowidjojo E, Nguyen B, Moukarzel L, Da Cruz Paula A, et al.
Gynecol Oncol
. 2025 Mar;
195:89-97.
PMID: 40081112
Objective: The molecular underpinnings of primary treatment-naïve endometrial carcinoma (EC) are well described. Here we sought to characterize the genomic landscape of distant metastatic EC. Methods: Distant metastatic ECs from...
2.
Varghese A, Perry M, Chou J, Nandakumar S, Muldoon D, Erakky A, et al.
Nat Med
. 2025 Jan;
31(2):466-477.
PMID: 39753968
Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present with advanced disease and are treated with cytotoxic therapy. Genomic biomarkers prognostic...
3.
Kalinsky K, Bianchini G, Hamilton E, Graff S, Park K, Jeselsohn R, et al.
J Clin Oncol
. 2024 Dec;
43(9):1101-1112.
PMID: 39693591
Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer...
4.
Yonemori K, Boni V, Min K, Meniawy T, Lombard J, Kaufman P, et al.
Gynecol Oncol
. 2024 Oct;
191:172-181.
PMID: 39442371
Objective: Imlunestrant is a next-generation oral selective estrogen receptor degrader designed to deliver continuous estrogen receptor (ER) target inhibition. EMBER is a phase 1a/b trial of imlunestrant, as monotherapy and...
5.
Neven P, Stahl N, Vidal M, Martin M, Kaufman P, Harbeck N, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5304-5313.
PMID: 39377773
Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in...
6.
Jhaveri K, Lim E, Jeselsohn R, Ma C, Hamilton E, Osborne C, et al.
J Clin Oncol
. 2024 Sep;
42(35):4173-4186.
PMID: 39241211
Purpose: Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in mutant breast cancer. This phase Ia/b trial determined the recommended...
7.
Wierda W, Shah N, Cheah C, Lewis D, Hoffmann M, Coombs C, et al.
Lancet Haematol
. 2024 Jul;
11(9):e682-e692.
PMID: 39033770
Background: Richter transformation usually presents as an aggressive diffuse large B-cell lymphoma, occurs in up to 10% of patients with chronic lymphocytic leukaemia, has no approved therapies, and is associated...
8.
Alshalalfa M, Goglia A, Swami N, Nguyen B, Hougen H, Khan A, et al.
Urol Oncol
. 2023 Apr;
41(5):253.e21-253.e26.
PMID: 37003878
Introduction: Emerging evidence suggests that metastasis is better described as a spectrum of disease rather than a binary state. A greater understanding of the genomic features that determine extent and...
9.
Tsai C, Nguyen B, Luthra A, Chou J, Feder L, Tang L, et al.
JAMA Netw Open
. 2022 Aug;
5(8):e2228083.
PMID: 36001319
Importance: Brain metastasis (BrM) in gastroesophageal adenocarcinoma (GEA) is a rare and poorly understood phenomenon associated with poor prognosis. Objectives: To examine the clinical and genomic features of patients with...
10.
Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack K, Kreitzer C, et al.
Clin Cancer Res
. 2022 Jun;
28(16):3603-3617.
PMID: 35670774
Purpose: Oncogenic alterations of the PI3K/AKT pathway occur in >40% of patients with metastatic castration-resistant prostate cancer, predominantly via PTEN loss. The significance of other PI3K pathway components in prostate...